Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Sutro Biopharma Inc

STRO ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$9.10

▼ -0.44%

Market Cap $150.89M · Vol 45.84K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$150.89M

Micro Cap

Div Yield

N/A

EPS Growth

+61.82%

YoY

RSI (14)

24.20

Momentum

Beta

1.50

vs Market

52W High

$43.85

79.25% below

52W Low

$7.16

27.09% above

Volume

45.84K

Avg 93.34K

P/B

N/A

Price-to-book

ROE

435.02%

Return on equity

Free Float

85.28%

Public shares

Shariah Compliance8 STANDARDS

✗ Sutro Biopharma Inc (STRO) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does STRO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.47%

-43.51%

-63.34%

-75.15%

YTD

-21.35%

-21.55%

-66.91%

-95.49%

Financials & Valuation

TTM · Annual

Total Revenue	$102.48M
Net Income	$-191,086,000.00
Revenue Growth (YoY)	-84.57%
Gross Margin	100.00%
Operating Margin	-102.41%
Net Profit Margin	-186.45%
ROE	435.02%
ROA · ROIC	-68.15% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	0.96
P/B	N/A
P/FCF	N/A
EPS Growth	+61.82%
Outstanding Shares	16.58M

Technical Indicators

50-Day SMA	$15.39
200-Day SMA	$23.03
RSI (14)	24.20
Beta	1.50
52-Week High	$43.85
52-Week Low	$7.16

Volume Today	45.84K
Avg Daily Volume (30D)	93.34K
Relative Volume	0.49x
Volatility (10D)	69.31
Volatility (30D)	82.53
Free Float	85.28%

Analyst Consensus

BUY

Current Price $9.10

Mean Target $47.23

52W Low$7.16 52W High$43.85

Current

Target

$7.16 $43.85

Current Analyst target

+419.02% upside potential · 14 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001T94MP6

ISINUS8693672011

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeUNT Unit

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -2.98% ARGX.BR argenx SE +0.35% ARGX argenx SE -0.55% GMAB.CO Genmab A/S +3.27% GMAB Genmab A/S +1.01%

Company Profile

Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.